Carboplatin can be used as a monotherapy or in combination with other antitumor drugs. When choosing a dose and dosage regimen, special literature should be used in each individual case. The drug is administered intravenously (IV) in the following dose regimens:
- 300 - 400 mg / m2 in / in infusion over 15-60 min or a 24-hour infusion;
- 100 mg / m2 in / in the drip for 15-60 minutes daily for 5 days;
Introduction of the preparation is repeated at intervals of not less than 4 weeks at rates of at least 100,000 platelet cells / .mu.l of blood neutrophils, and not less than 2000 cells / l blood. Introduction of fluid before or after application of carboplatin, as well as achieving forced diuresis is required.
Depending on the state of the bone marrow or kidney function, the therapeutic dose of carboplatin can be corrected as follows:
- PIn reducing the number of platelets to 50,000 / μL and / or neutrophils to 500 / μL, no previous dose adjustment is required for previous carboplatin therapy;
- PFor the observed minimum platelet counts less than 50,000 / μL and / or neutrophils less than 500 / μL for the previous course of carboplatin therapy, consideration should be given to reducing the next dose by 25% in both monotherapy and combined treatment regimens;
- PIn violation of kidney function (creatinine clearance less than 60 ml / min), the risk of toxic effects of carboplatin increases, and therefore recommended doses of carboplatin are at creatinine clearance of 41-59 ml / min - 250 mg / m2, with the clearance of creatinine 16-40 ml / min - 200 mg / m2;
- patients with risk factors, such as, for example, previous courses of myelosuppressive therapy, age over 65 years, low functional status (ECOG-Zubrod 2-4 or the Karnovsky index below 80%), it is recommended to reduce the initial dose of carboplatin by 20-25%.
Determination of the dose by the formula
The initial dose of the preparation in milligrams can be determined from the Calvert formula, which describes the dependence of the glomerular filtration rate (GFR in ml / min) and the desired concentration of carboplatin in the blood plasma versus timeAUC in mg / ml x min):
Total Dose (mg) = AUC х (СГФ +25)
| Preferred | Planned chemotherapy | Status of the patient in |
| AUC value | Carbothers | treatment |
| 5-7 mg / ml.min | Monotherapy | Previously untreated |
| 4-6 mg / ml. Min | Monotherapy | Previously treated |
| 4-6 mg / ml. Min | In combination with cyclophosphamide | Previously untreated |
Preparation for intravenous administration
The drug should be dissolved in water for injection at a concentration of 10 mg / ml. The solution obtained before intravenous administration is diluted to a concentration of 0.5 mg / ml with a 5% solution of dextrose or 0.9 % solution of sodium chloride.
Dilute drug solutions are stable for 8 hours at 25 ° C and for 24 hours when stored in a refrigerator at 4 ° C.